We are live on ! Find out more
ONCT

Oncternal Therapeutics, Inc. Common Stock
ONCT

Delisted

ONCT was delisted on the 2nd of December, 2024.

Back to rankings

Fund managers haven’t disclosed any holdings of ONCT yet.

ONCT Hedge Fund Activity: Q1 2026 in Review

1 of the 8,141 institutional investors tracked by Wall St. Rank reported a position in Oncternal Therapeutics, Inc. Common Stock (ONCT) for Q1 2026, worth a combined $74 — down 56% from $169 a quarter earlier.

Sellers outnumbered buyers: 1 fund closed out of ONCT and 0 opened new positions — a net loss of 1 holder — while 0 trimmed existing stakes and 0 added.

The largest seller was BNP Paribas Financial Markets, exiting entirely with an estimated $96 sold.

  • 1 institutional investor held Oncternal Therapeutics, Inc. Common Stock (ONCT) as of Q1 2026, down from 2 in Q4 2025.
  • Funds reported $74 of Oncternal Therapeutics, Inc. Common Stock stock for Q1 2026, down 56% quarter-over-quarter.
  • 0 funds opened new Oncternal Therapeutics, Inc. Common Stock positions in Q1 2026 and 1 closed out, a net change of -1 holder.
  • The largest Oncternal Therapeutics, Inc. Common Stock seller in Q1 2026 was BNP Paribas Financial Markets, an estimated $96 sold.

Based on aggregated 13F filings for Q1 2026.